Mustang Bio (MBIO) Short term Debt (2019 - 2020)
Mustang Bio's (MBIO) quarterly Short term Debt came in at $5.0 million in Q2 2020, up 60.0% quarter-over-quarter from $3.1 million in Q1 2020.
Powered by 
Analysis
Mustang Bio (MBIO) Short term Debt (2019 - 2020) Analysis & Trends
Mustang Bio (MBIO) has reported Short term Debt for 2 consecutive years, with $5.0 million the latest figure, recorded in Q2 2020.
- On a quarterly basis, Short term Debt changed N/A year-over-year to $5.0 million in Q2 2020; TTM through Jun 2020 was $5.0 million, a N/A change from a year earlier, with the FY2019 full-year figure at $1.2 million, changed N/A from the prior year.
- Short term Debt was $5.0 million for Q2 2020 at Mustang Bio, up from $3.1 million in the prior quarter.
- Over five years, Short term Debt peaked at $5.0 million in Q2 2020 and troughed at $1.2 million in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn |
| 10 | Mustang Bio | 3.64 Mn | 3.64 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2020 | 5.00 Mn |
| Mar 31, 2020 | 3.13 Mn |
| Dec 31, 2019 | 1.25 Mn |